within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG04_Belimumab;

model Belimumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.967592592592593e-09,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.0037,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0025499999999999997,
    k12 = 2.6388888888888892e-09,
    k21 = 2.6388888888888892e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Belimumab</td></tr><tr><td>ATC code:</td><td>L04AG04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.17</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Belimumab is a fully human monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS or BAFF) and is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE) in adults and pediatric patients. It is administered as an adjunct to standard therapy and reduces disease activity by limiting the survival and differentiation of B cells.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with SLE following intravenous administration. Mixed sex, adult patients, typical body weight 76 kg.</p><h4>References</h4><ol><li><p>Struemper, H, et al., &amp; Cai, W (2013). Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. <i>Journal of clinical pharmacology</i> 53(7) 711–720. DOI:<a href=\"https://doi.org/10.1002/jcph.104\">10.1002/jcph.104</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23681782/\">https://pubmed.ncbi.nlm.nih.gov/23681782</a></p></li><li><p>Dimelow, R, et al., &amp; Struemper, H (2021). Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. <i>Clinical pharmacology in drug development</i> 10(6) 622–633. DOI:<a href=\"https://doi.org/10.1002/cpdd.889\">10.1002/cpdd.889</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33245847/\">https://pubmed.ncbi.nlm.nih.gov/33245847</a></p></li><li><p>Zhou, X, et al., &amp; Ma, P (2021). Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. <i>Drugs in R&amp;D</i> 21(4) 407–417. DOI:<a href=\"https://doi.org/10.1007/s40268-021-00363-2\">10.1007/s40268-021-00363-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34628605/\">https://pubmed.ncbi.nlm.nih.gov/34628605</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AG04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Belimumab;
